Author

Daniel Serin

Observed name: D Serin

Observed institutions: Lyon 1 Université, Inserm, Universidad de Alcalá, Université de Montpellier, University of Washington, Aix-Marseille Université, Institut Gustave Roussy, Sanofi (France), Centre Hospitalier Universitaire de Besançon, Institut Salah-Azaïz, Centre Georges François Leclerc, Centre Hospitalier de Bretagne Sud, Hôpital Bretonneau, Centre Léon Bérard, Centre Eugène Marquis, Hôpital Lyon Sud, Centre Hospitalier Universitaire de Caen Normandie, Centre Hospitalier de Mulhouse, Centre François Baclesse, Institut Claudius Regaud, Haute École Louvain en Hainaut, Centre Hospitalier Régional Universitaire de Brest, bioMérieux (France), Institut Paoli-Calmettes, Centre Antoine Lacassagne, Institut Jean Godinot, Institut Sainte Catherine, Bicêtre Hospital, Fédération Hospitalière de France, Institut Strauss, Institut Curie

ORCID: 0000-0002-9343-4793

Observed ORCID: 0000-0002-9343-4793

OpenAlex ID: A5111634771

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

2006 · Henri Roché, Pierre Fumoleau, et al. · Journal of Clinical Oncology · 578

PDF

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

2013 · Xavier Pivot, Gilles Romieu, et al. · The Lancet Oncology · 344

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

2011 · Elisabeth Luporsi, Fabrice André, et al. · Breast Cancer Research and Treatment · 333

PDF

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

2009 · Marc Spielmann, Henri Roché, et al. · Journal of Clinical Oncology · 299

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

2007 · Bruno P. Coudert, Remy Largillier, et al. · Journal of Clinical Oncology · 133

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

2019 · Xavier Pivot, Gilles Romieu, et al. · The Lancet · 131

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

2010 · Jean-Marc Extra, Eric C. Antoine, et al. · The Oncologist · 107

Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial

2003 · Pierre Fumoleau, Pierre Kerbrat, et al. · Journal of Clinical Oncology · 105

Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy After Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial

2007 · Alain Toledano, David Azria, et al. · Journal of Clinical Oncology · 89

Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: Long-term results of the ARCOSEIN multicenter randomized study

2006 · Alain Toledano, Pascal Garaud, et al. · International Journal of Radiation Oncology*Biology*Physics · 89

A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results

2006 · Jacques Rouëssé, Brigitte de la Lande, et al. · International Journal of Radiation Oncology*Biology*Physics · 74

Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives

2016 · Jennifer Cautela, Nathalie Lalevée, et al. · International Journal of Cardiology · 41

Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial

2012 · Bruno Coudert, Bernard Asselain, et al. · The Oncologist · 36

Impact of organised programs on colorectal cancer screening

2008 · François Eisinger, Laurent Cals, et al. · BMC Cancer · 27

PDF

[For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres].

2004 · Ivan Krakowski, François Boureau, et al. · PubMed · 27

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

2011 · Jocelyne Jacquemier, Jean-Marie Boher, et al. · Breast Cancer Research · 26

PDF

Cancer screening in France: subjects’ and physicians’ attitudes

2007 · François Eisinger, Jean-Yves Blay, et al. · Cancer Causes & Control · 25

PDF

Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer

2006 · Thierry Petit, Abdellatif Benider, et al. · Anti-Cancer Drugs · 24

Does Concurrent Radiochemotherapy Affect Cosmetic Results in the Adjuvant Setting After Breast-Conserving Surgery? Results of the ARCOSEIN Multicenter, Phase III Study: Patients’ and Doctors’ Views

2007 · Alain H. Toledano, Marc A. Bollet, et al. · International Journal of Radiation Oncology*Biology*Physics · 23

Hereditary breast cancer, circa 1750

1998 · François Eisinger, Hagay Sobol, et al. · The Lancet · 22

A Multicenter Study to Assess a Systematic Screening of Occupational Exposures in Lung Cancer Patients

2023 · Olivia Pérol, Nadège Lepage, et al. · International Journal of Environmental Research and Public Health · 20

PDF

Development and feasibility of a set of quality indicators relative to the timeliness and organisation of care for new breast cancer patients undergoing surgery

2012 · Marie Ferrua, Mélanie Couralet, et al. · BMC Health Services Research · 20

PDF

Activité physique et survie après cancer

2012 · Isabelle Romieu, Marina Touillaud, et al. · Bulletin du Cancer · 19

Assessment of Care by Breast Cancer Patients Participating or Not Participating in a Randomized Controlled Trial: A Report With the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer

2007 · Claire Julian-Reynier, Jean Genève, et al. · Journal of Clinical Oncology · 17

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup

2019 · Véronique D'Hondt, Jean-Luc Canon, et al. · European Journal of Cancer · 15

Works count: 93

Citation count: 2,722

H-index: 20

I10-index: 27